Replicon plasmids encoding an alphavirus RNA replicase constitute an alternative to conventional DNA plasmids with promise for DNA vaccination in humans. Replicase activity amplifies the levels of transgene mRNA through a copying process involving double-stranded (ds) RNA intermediates, which contribute to vaccine immunogenicity by activating innate antiviral responses. Toll-like receptor 3 (TLR3) is a dsRNA innate immune receptor expressed by antigenpresenting dendritic cells (DCs). Here, we test the hypothesis that TLR3 is necessary for the immunogenicity of replicon plasmid-based DNA vaccines. We show that mouse CD8a + DC phagocytose dying replicon plasmid-transfected cells in vitro and are activated in a TLR3-dependent manner by dsRNA present within those cells. However, we find that cytotoxic T-cell responses to a replicon plasmid intramuscular vaccine are not diminished in the absence of TLR3 in vivo. Our results underscore the potential role of TLR3 in mediating immune activation by dsRNA-bearing replicon plasmidtransfected cells and indicate that other innate sensing pathways can compensate for TLR3 absence in vivo.
Introduction
Most currently available vaccines work by eliciting antibody responses and are relatively inefficient at inducing cellular immunity. Yet, the latter is vital for resistance to a wide panel of pathogens, including Mycobacterium tuberculosis and the malaria parasite, as well as being a critical element of anti-tumor immunotherapy. Thus, there is a need for improved vaccination approaches that elicit potent CD4 + and CD8 + T-cell responses. 1 In mice, naked plasmid DNA immunization is very effective at promoting cytotoxic T-lymphocyte (CTL) responses, yet DNA vaccines have yielded lessimpressive results in human trials. 2, 3 This may be due in part to the fact that in humans, DNA vaccines are administered in a small volume. Experimental studies in mice have shown that DNA vaccines lose immunogenicity when the volume injected is reduced, suggesting that local tissue damage and consequent inflammation are critical for vaccine efficacy. 4 As equivalent levels of tissue damage would be unacceptable in a clinical setting, other strategies must be explored to increase the immunogenicity of DNA vaccines.
One promising approach has been the development of replicon-based DNA vaccines, which in some studies are superior to conventional DNA vaccines at eliciting immune responses. Replicon plasmids encode an alphavirus replicase, an RNA-dependent RNA polymerase that copies and, thereby, greatly amplifies the plasmidencoded transgene RNA. 5 Amplification of the transgene RNA allows greater levels of antigen expression and this was initially thought to account for the increased immunogenicity of replicon-based plasmids. 6, 7 However, it is now clear that these vaccines effectively activate the innate arm of the immune system, which dictates the subsequent adaptive response. 8 Indeed, the immunogenicity of replicon plasmid-based DNA vaccines is dependent on the induction of type I interferons (IFN-a/b), a hallmark of innate virus detection. 9 Thus, the potency of replicon-based DNA vaccines may be due to the fact that they mimic virus infection.
The alphavirus replicases act through the formation of double-stranded (ds) RNA intermediates, which are a potent inducers of innate antiviral responses. 10 dsRNA can also directly activate dendritic cells (DC) to allow coupling of innate and adaptive immunity. 11 Toll-like receptor 3 (TLR3) was the first receptor described to couple detection of dsRNA with transcription of innate response genes, including those encoding the type I IFNs. [12] [13] [14] In the mouse, the CD8a + subset of DC expresses the highest levels of TLR3 and, therefore, has the ability to respond readily to dsRNA. 15 We have shown earlier that CD8a + DCs can ingest material from dying cells and use TLR3 to detect dsRNA associated with virus infection. 16 The triggering of TLR3 in this setting promotes CD8a + DC activation and leads to crosspriming of T cells specific for antigens present within the virally infected cells.
dsRNA is generated within cells that are transfected with replicon-based plasmids, leading to the activation of the 2 0 -5 0 -oligoadenylate antiviral pathway, which culminates in the induction of apoptosis. 8 Thus, we hypothesized that TLR3-mediated activation of DCs by replicon-transfected cells bearing dsRNA might underlie the adaptive immune response to replicon-based DNA vaccines. Here, we show that mouse CD8a + DCs are activated through a TLR3-dependent pathway by exposure to replicon plasmid-transfected cells. However, TLR3 is not required for the immunogenicity of repliconbased DNA vaccination in vivo.
Results

Induction of apoptosis in cells transfected with replicon vector
VERO cells were transfected by electroporation with equal amounts of a Sindbis virus-based replicon plasmid (pSIN-GFP) or a conventional plasmid (pEGFP), both encoding green fluorescent protein (GFP). After 6 h of transfection, 15% of replicon transfected and 54% of cells transfected with the conventional control plasmid expressed high levels of GFP (Figure 1a ). Although cells expressing GFP encoded by the conventional plasmid showed a broad distribution of GFP fluorescence levels, replicon plasmid-transfected cells showed a high proportion of cells with high levels of GFP (Figure 1a) . This difference in transgene expression is most likely attributable to the replicon-driven amplification of the transgene RNA, as described earlier. 17 To determine the level of apoptosis induced by transgene expression, we measured the frequency of annexin V + and 4 0 ,6-diamidino-2-phenylindole-negative (DAPI À ) cells in VERO cell cultures 6 h after electroporation. Among the GFP À cell populations, only 3-5% of cells were annexin V + and DAPI À irrespective of whether they were electroporated with replicon or conventional plasmid DNA (Figure 1a) . In the population transfected with the conventional plasmid, the GFP + cells showed a similarly low basal level of apoptotic cells (Figure 1a) . In contrast, at least 25% of GFP + cells in the population transfected with a replicon plasmid showed signs of apoptosis (annexin V + and DAPI 
Uptake of transfected cells by splenic DCs
We next compared the uptake of VERO cells transfected with replicon plasmid or conventional plasmid DNA by DCs. After 6 h of electroporation, VERO cells were labeled with the membrane dye PKH26 and were cocultured with CD11c-enriched splenic cells. Uptake of PKH26-labeled cellular material by CD8a + DCs was determined by flow cytometry. 19 Overall, 72 and 64% of CD8a + DCs stained positive for the membrane dye PKH26 after incubation with VERO cells transfected with pSIN-GFP and pEGFP, respectively (Figure 3a) . The dye transfer reflected the true uptake of cells or cell debris by DCs, as it was blocked by latrunculin, which prevents actin-dependent phagocytic and macropinocytic processes (data not shown; see reference Schulz and Reis e Sousa 19 ). In multiple experiments, no significant differences were seen in the uptake of replicon plasmidtransfected versus conventional plasmid-transfected VERO cells (Figure 3b ). Thus, CD8a
+ DCs have equal access to cellular material from replicon plasmidtransfected or conventional plasmid-transfected VERO cells despite the increased frequency of apoptosis in the former population.
DC activation by replicon plasmid-transfected VERO cells
Splenocytes enriched with CD8a
+ DCs were co-cultured with VERO cells transfected with replicon and conven- Role of TLR3 in replicon vaccines SS Diebold et al tional plasmid DNA, and DC activation was monitored by the production of interleukin-6 (IL-6). 16 VERO cells transfected with the conventional plasmid DNA did not induce DC activation at any of the ratios tested (Figure 4a ). In contrast, dose-dependent activation was seen when the DCs were incubated with VERO cells that had been transfected with the replicon-based plasmid (Figure 4a) . However, the response was weaker than that to poly I:C-transfected cells, which served as a positive control (Figure 4a ). To test whether this was due to the fact that only 10-15% of VERO cells were actually transfected with replicon plasmid, we sorted GFP + VERO cells and repeated the co-culture experiments. When the GFP + fraction of replicon plasmid-transfected VERO cells was used for the co-culture experiment, DC activation as measured by IL-6 induction exceeded that observed with polyI:C-associated VERO cells (Figure 4b ).
The equivalent GFP + fraction from conventional plasmid-transfected cells was not stimulatory (Figure 4b ). Sorted GFP À cells from replicon plasmid or conventional plasmid-transfected samples also did not induce IL-6 (data not shown). Thus, the ability of DNA-transfected cells to induce DC activation correlates with their dsRNA content.
DC activation by replicon plasmid-transfected cells is TLR3-dependent
To test whether the activation of CD8a + DCs in response to ingested material from replicon plasmid-transfected cells was mediated by the recognition of dsRNA associated with the cellular material, the activation of wild-type CD8a + DCs was compared with the activation of CD8a
+ DCs from TLR3-deficient mice. TLR3-deficient Role of TLR3 in replicon vaccines SS Diebold et al CD8a + DCs were unable to respond to replicon plasmidtransfected VERO cells (Figure 4c ). As expected, such DCs also failed to be activated by polyI:C-transfected VERO cells or by soluble polyI:C, whereas their response to CpG 1668 oligonucleotide, which triggers TLR9, was unaffected (Figure 4c ). Thus, TLR3-mediated recognition of cell-associated dsRNA allows CD8a + DCs to respond to cells transfected with replicon plasmid DNA.
As the expression of the replicon plasmid-endoded transgene induced apoptosis (Figures 1a and c) and because cell death could be sufficient to promote DC activation, we normalized for the level of apoptosis by irradiating cells before co-culture with DCs. To ensure efficient transgene expression, VERO cells were cultured for 12 h post-electroporation. Cells were then ultravioletirradiated followed by another 12 h of cell culture to allow the cells to undergo irradiation-induced apoptosis/secondary necrosis. After 12 h irradiation, the frequency of annexin V + cells in replicon versus conventional plasmid-electroporated samples was identical (data not shown). When the ultraviolet-irradiated cells were subsequently co-cultured with splenic DCs, a slight increase in IL-6 level was observed in response to cells electroporated with conventional plasmid, but the levels of cytokine were lower than in response to replicon plasmid-transfected cells (Figure 4d ). Thus, induction of cell death in cells expressing conventional plasmid DNA might increase their stimulatory ability but this falls markedly short of that observed for cells electroporated with replicon plasmid. This can probably be attributed to the presence of dsRNA in the latter.
CD8a
+ T cell priming in response to DNA vaccination is TLR3-independent As activation of CD8a + DC by replicon-expressing cells was TLR3-dependent, we wondered whether the immunogenicity of replicon vector-based DNA vaccines also depended on TLR3. We immunized wild-type and TLR3-deficient mice intramuscularly with replicon or conventional plasmid vectors expressing the model antigen ovalbumin (OVA) and used anti-CD40 antibody as adjuvant to increase the immune response. Three weeks later, we analyzed the number of OVA-specific CD8 + T cells in the spleen and in vivo cytoxicity against OVA peptide-pulsed targets. Despite a high variability within groups, overall numbers of OVA-specific CD8 + T cells were not significantly different for replicon and conventional plasmid-vaccinated mice (Figure 5a ). In vivo cytotoxic activity against OVA was also similar between wild-type and TLR3 À / À mice independent of the type of plasmid used for vaccination (Figure 5b ). The same result was obtained in mice vaccinated in the absence of anti-CD40 antibody (data not shown). Thus, although activation of CD8a + DCs in response to replicon-expressing cells in vitro is dependent on TLR3, in vivo CTL priming upon intramuscular injection of replicon DNA is TLR3-independent.
Discussion
In this study, we tested the hypothesis that the immunogenicity of replicon-based plasmid vectors used for DNA vaccination is mediated by TLR3-dependent activation of cells of the innate immune system such as DCs. We show that dsRNA, the putative agonist ligand for TLR3, is generated within cells transfected with replicon plasmid vector and that co-culture of such cells with CD8a + DCs, the primary mouse APC involved in cross-priming, 20 leads to TLR3-dependent DC activation. However, when mice were vaccinated with replicon plasmid via the intramuscular route, we found that CTL responses directed against the protein encoded by the transgene were independent of TLR3. The discrepancy between the TLR3 dependence of replicon plasmidmediated DC activation in vitro and the redundancy of TLR3 for immunization with replicon plasmids in vivo highlights the complex nature of innate recognition of dsRNA in vivo.
Despite the repeated involvement of CD8a + DCs in most models of cross-priming, 20 the observation that induction of CTL responses by intramuscular injection of replicon plasmid DNA is independent of TLR3 suggests that CD8a + DCs may be dispensable for the response to replicon vaccination. This might indicate that such DCs do not have access to replicon-transfected cells in vivo. We focused on intramuscular vaccination, as this is the route most frequently used for DNA vaccination, particularly in humans. Skin delivery of replicon could conceivably allow greater involvement of CD8a + DCs present in draining lymph nodes. Alternatively, it is possible that CD8a + DCs are involved even in responses to intramuscular replicon vaccinations but that other receptors substitute for TLR3 in CD8a + DC activation. 
Role of TLR3 in replicon vaccines SS Diebold et al
In this regard, IFN-a/b produced by the transfected cells themselves could potentially activate DCs in trans, promoting cross-priming, as suggested earlier.
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A more likely alternative is that the response to replicon-based plasmids in vivo reflects not only cross-priming by DCs of material acquired from heterologous-transfected cells but also endogenous antigen presentation by DCs that were directly transfected in vivo, as observed for DNA vaccination by conventional plasmids. [22] [23] [24] In that situation, TLR3 would not be expected to operate and DC activation would therefore ensue from triggering of other innate receptors. It can be noted that DNA has the potential to trigger TLR9 but, interestingly, conventional plasmid DNA vaccines are still immunogenic in TLR9-deficient mice. 25, 26 In fact, conventional plasmid DNA vaccines appear to work independently of most TLRs as no reduction in vaccine efficiency is observed in MyD88 À/À mice. 25 However, because TLR3 uses the adaptor TRIF (TIR domain-containing adaptor protein inducing interferon-b) rather than MyD88, it remained possible that TLR3 was required. This study formally excludes a requirement for TLR3 in mediating the immunogenicity of either conventional or replicon DNA vaccines. Thus, TLRs appear largely redundant in immune responses to DNA vaccination.
All cells possess several non-TLR cytoplasmic receptors for dsRNA that activate cell-intrinsic antiviral pathways.
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These include the 2 0 -5 0 -oligoadenylate synthetase system, which acts to induce cleavage of cellular RNAs and/or induce apoptosis in virus-infected cells. 11 It can be noted that cells transfected with replicon plasmid DNA activate the 2 0 -5 0 -oligoadenylate production and mice deficient in RNAseL, a mediator of the 2 0 -5 0 -oligoadenylate antiviral effect, display reduced CTL responses to replicon plasmid vaccination. 8 However, RNAseL alone does not lead to the induction of IFN-a/b, which is also essential for the immunogenicity of replicon-based DNA vaccines. 27 It is therefore likely that vaccination with replicon plasmid DNA leads to activation of one or another of the recently discovered IFN-a/ b-inducing cytoplasmic sensors for viral nucleic acids.
These include the RNA helicases MDA5 and RIG-I and the DNA sensor, DAI, all of which induce IFN-a/b gene transcription through a pathway involving TANK-binding kinase-1 (TBK1). [28] [29] [30] [31] [32] Interestingly, although DAI is dispensable, TBK1 is essential for immune responses to DNA vaccination with a conventional plasmid vector. 33 These observations suggest that MDA5 and/or RIG-Imediated immune activation might mediate the efficacy of DNA vaccines with replicon-based or conventional plasmids.
Materials and methods
Cells
African green monkey kidney (VERO) fibroblasts were grown in serum-free SF-VPM medium (Invitrogen, Paisley, UK).
C57BL/6 mice were obtained from Charles River (Margate, UK). TLR3 À/À and C57BL/6 SJL-CD45.1 congenic mice were bred at Cancer Research UK. Splenocytes were prepared by digestion with Liberase CI and DNaseI (Roche, Welwyn Garden City, Hertfordshire, UK). CD11c-enriched cells were prepared using anti-CD11c MACS beads (Miltenyi, Bergisch Gladbach, Germany) according to the manufacturer's instructions, and cells were separated on an AUTOMACS apparatus (Miltenyi). Sorted CD8a + DCs were purified from splenic suspensions as described. 34 
Plasmid vectors
The following plasmid vectors were used: pEGFP-C1 was purchased from Clontech (Saint-Germain-en-Laye, France) and pcDNA3-DOVA was cloned as described. 35 The replicon vectors were obtained from Chiron Corporation (Emeryville, CA, USA). They encode Sindbis replicase, which drives the replication of the encoded transgene and are derived from pSIN1.5-bgal. The GFPencoding replicon pSIN1.5-EGFP (pSIN-GFP) has been described, 17 whereas the sequence of ovalbumin missing the leader sequence was excised from pcDNA3-DOVA and cloned into the pSIN1.5 replicon vector.
In vitro transfection
VERO cells were harvested, resuspended in electroporation buffer containing plasmid DNA and electroporated at 300 mV and 150 mF. 36 Cells were cultured for 6 h before transgene expression and apoptosis induction was analyzed. Cells were used for in vitro DC co-cultures or in vivo vaccination 6 h after electroporation. Cells transfected with GFP-encoding replicon or conventional plasmid were used unsorted or after sorting of GFP + and GFP À cells on a MoFlo cell sorter. As controls, cells were electroporated with 10 mg of poly I:C (GE Healthcare, Chaltfont St Giles, Buckinghamshire, UK) at 300 mV and 150 mF. Poly I:C-electroporated cells were used directly for staining of dsRNA and for in vitro co-culture with splenic DCs.
Apoptosis
VERO cells were harvested and resuspended in annexin V binding buffer containing annexin V conjugated to Alexa647 (Invitrogen). Stained cells were analyzed by flow cytometry on a FACScalibur (BD Biosciences, Oxford, UK) after the addition of propidium iodide. For induction of apoptosis, VERO cells were irradiated in a ultraviolet cross-linker with a dose of 15 mJ cm À2 for 12 h post-electroporation. Cells were cultured an additional 12 h to allow the cells to undergo apoptosis/ secondary necrosis and were subsequently analyzed by annexin V staining and co-cultured with splenic DCs.
Immunostaining VERO cells were fixed in 4% paraformaldehyde and subsequently stained with anti-dsRNA antibody (clone K1; English & Scientific Consulting Bt., Szirák, Hungary) in the presence of saponin to allow for cell permeabilization. Cells were then stained with a biotinylated rat antimouse secondary antibody (Jackson ImmunoResearch, from Stratech, Newmarket Suffolk, UK) followed by incubation with fluorescently labeled streptavidin (BD Biosciences). Samples were analyzed by flow cytometry on a FACScalibur (BD Biosciences).
Uptake assay
Transfected and mock-treated VERO cells were labeled with PKH26 and co-cultured with CD11c-enriched splenic DCs for 4 h at a ratio of 5:1. Uptake of material from PKH26-labeled VERO cells by CD8a + splenic DCs In vitro activation assay VERO cells were co-cultured with sorted splenic CD8a + DCs at ratios of 1:5, 1:1 and 5:1. As controls for DC activation, splenic DCs were cultured in the presence of 100 mg ml À1 polyI:C and 0.5 mg ml À1 CpG 1668 oligonucleotide (MWG, Edersberg, Germany). After overnight culture, levels of IL-6 in the co-culture supernatant were determined by sandwich ELISA using anti-mouse IL-6 antibodies from BD Biosciences (clones MP5-20F3 and MP5-32C11 as capture and detection antibody, respectively).
Vaccination
For DNA vaccination, C57BL/6 and TLR3 À/À mice were injected intramuscularly with 50 mg of replicon and conventional plasmid DNA. The amount of plasmid DNA was chosen to allow for equivalent levels of T-cell expansion and CTL induction. In some experiments, mice were additionally injected with 50 mg of anti-CD40 antibody (clone FGK-45; BD Biosciences) intraperitoneally. Three weeks after vaccination, peptide-pulsed (200 ng of SIINFEKL) and unpulsed splenocytes labeled with different amounts of carboxyfluorescein succinimidyl ester (CFSE) were injected intravenously to determine antigen-specific target cell killing. The next day, splenocytes were isolated by DNAse and liberase digestion, and the frequencies of peptide-loaded and unloaded CFSE-stained target cells were determined by flow cytometry. Antigen-specific target cell killing was calculated using the following formula: (1À%CFSE peptide / %CFSE no peptide ) Â 100. In addition, splenocytes from vaccinated mice were stained with H-2K b /SIINFEKL pentamers (ProImmune Ltd., Oxford, UK), anti-CD8a and anti-Thy1.2 antibodies (both BD Biosciences), and the frequency of antigen-specific CD8 T cells was determined by flow cytometry. Absolute numbers of pentamer + cells were determined by the addition of a fixed number of Calibrite beads (BD Biosciences) to the samples before flow cytometric acquisition.
Statistical analysis
Data were analyzed using a two-tailed Student's t-test (Prism program; GraphPad software, La Jolla, CA, USA). Differences were considered significant at a P-value o0.05.
